REFERENCES
1. Galac S, Fracassi, F. Canine endocrinology. In: CH 23: hypothalamus and pituitary gland: anatomy and physiology. Edra Publishing US LLC, 2024; pp. 107-10.
2. Rijnberk A, Kooistra HS. Chapter 2: Hypothalamus-pituitary system. In: Clinical endocrinolongy of dogs and cats, an illustrated text. Schlütersche, 2010; pp. 13-54.
5. Del Magno S, Fracassi F, Grinwis GC, et al. Sequential treatment of a large pituitary corticotroph neoplasm and associated neurological signs in a dog. J Am Anim Hosp Assoc. 2019;55:e552-02.
6. Steele MME, Lawson JS, Scudder C, et al. Transsphenoidal hypophysectomy for the treatment of hypersomatotropism secondary to a pituitary somatotroph adenoma in a dog. J Vet Intern Med. 2024;38:351-7.
7. Blokland-Post K, Grinwis G, Tellegen A, Meij B. Transsphenoidal hypophysectomy as a treatment for Rathke's cleft cyst in a dog. Vet Record Case Rep. 2022;10:e427.
8. Lehner L, Garamvölgyi R, Jakab C, Kerekes Z, Czeibert K. A recurrent suprapituitary ependymal cyst managed by endoscopy-assisted transsphenoidal surgery in a canine: a case report. Front Vet Sci. 2019;6:112.
9. Hyde BR, Martin LG, Chen AV, et al. Clinical characteristics and outcome in 15 dogs treated with transsphenoidal hypophysectomy for nonfunctional sellar masses. Vet Surg. 2022;52:69-80.
10. Martin L, Owen T, Chen-Allen A, Turner A, Carrera-Justiz S, Bruyette D. Clinical characteristics and outcome in dogs treated with transsphenoidal hypophysectomy for non-functional sellar masses. J Vet Intern Med. 2016;30:1941.
11. Owen T, Chen A, Martin L. Why, when, how and post-operative care of dogs undergoing transphenoidal hypophysectomy for large sellar masses. J Vet Intern Med 2016;30:1939. Available from: https://academic.oup.com/jvim/article/30/6/1929/8449772?login=false [Last accessed on 2 Jun 2026].
12. Owen TJ, Martin LG, Chen AV. Transsphenoidal surgery for pituitary tumors and other sellar masses. Vet Clin N Am Anim Pract. 2018;48:129-51.
13. Corsello A, Di Dalmazi G, Pani F, et al. Dandy: his contributions to pituitary surgery in the context of the overall Johns Hopkins Hospital experience. Pituitary. 2017;20:683-91.
14. Meij B, Voorhout G, Gerritsen R, Grinwis G, Ijzer J. Lymphocytic hypophysitis in a dog with diabetes insipidus. J Comp Pathol. 2012;147:503-7.
15. Rzechorzek NM, Liuti T, Stalin C, Marioni-Henry K. Restored vision in a young dog following corticosteroid treatment of presumptive hypophysitis. BMC Vet Res. 2017;13:63.
16. Bertolini G, Rossetti E, Caldin M. Pituitary apoplexy-like disease in 4 dogs. J Vet Intern Med. 2007;21:1251.
17. Tanaka S, Suzuki S, Oishi M, Soeta S, Namiki R, Hara Y. Adrenocorticotropic hormone-producing pituitary adenoma with pituitary apoplexy treated by surgical decompression: a case report. BMC Vet Res. 2022;18:397.
18. Galli G, Bertolini G, Dalla Serra G, Menchetti M. Suspected pituitary apoplexy: clinical presentation, diagnostic imaging findings and outcome in 19 dogs. Vet Sci. 2022;9:191.
19. Woelfel CW, Mariani CL, Nolan MW, et al. Presumed pituitary apoplexy in 26 dogs: clinical findings, treatments, and outcomes. J Vet Intern Med. 2023;37:1119-28.
20. Barnhart KF, Edwards JF, Storts RW. Symptomatic granular cell tumor involving the pituitary gland in a dog: a case report and review of the literature. Vet Pathol. 2001;38:332-6.
21. Ishino H, Takekoshi S, Teshima T, Uchida K, Sakonju I, Hara Y. Hyperadrenocorticism caused by a pituitary ganglioglioma in a dog. Vet Pathol. 2019;56:609-13.
22. Polledo L, Grinwis GCM, Graham P, Dunning M, Baiker K. Pathological findings in the pituitary glands of dogs and cats. Vet Pathol. 2018;55:880-8.
23. Miller MA, Bruyette DS, Scott-Moncrieff JC, et al. Histopathologic findings in canine pituitary glands. Vet Pathol. 2018;55:871-9.
24. Snyder J, Lipitz L, Skorupski K, Shofer F, Van Winkle T. Secondary intracranial neoplasia in the dog: 177 cases (1986-2003). J Vet Intern Med. 2008;22:172-7.
25. Gutierrez-Quintana R, Carrera I, Dobromylskyj M, Patterson-Kane J, Ortega M, Wessmann A. Pituitary metastasis of pancreatic origin in a dog presenting with acute-onset blindness. J Am Anim Hosp Assoc. 2013;49:403-6.
26. Tamura S, Tamura Y, Suzuoka N, Ohoka A, Hasegawa T, Uchida K. Multiple metastases of thyroid cancer in the cranium and pituitary gland in two dogs. J Small Anim Pract. 2006;48:237-9.
27. Menchetti M, De Risio L, Galli G, et al. Neurological abnormalities in 97 dogs with detectable pituitary masses. Vet Q. 2019;39:57-64.
28. Zou D, Yang Y, Gao R, et al. Long-term pituitary function following transsphenoidal surgery for non-functional pituitary neuroendocrine tumor with apoplexy: a single-center retrospective analysis. Sci Rep. 2025;15:19226.
29. Miller MA, Piotrowski SL, Donovan TA, et al. Feline pituitary adenomas: correlation of histologic and immunohistochemical characteristics with clinical findings and case outcome. Vet Pathol. 2020;58:266-75.
30. Wang MTM, Meyer JA, Danesh-Meyer HV. Neuro-ophthalmic evaluation and management of pituitary disease. Eye. 2024;38:2279-88.
31. Shah A, Mohamed Elsanafiry M. Diaphragma sellae: anatomical and surgical implication in surgery for pituitary adenomas - Highlighting contributions by Goel. J Craniovertebr Junction Spine. 2018;9:135.
32. Meij BP, Van Stee LL. Transsphenoidal surgery for pituitary tumors. Vet Clin N Am Anim Pract. 2025;55:95-118.
33. Teshima T, Hara Y, Shigihara K, et al. Coexistence of corticotroph adenoma and thyrotroph hyperplasia in a dog. J Vet Med Sci. 2009;71:93-8.
34. Lillehei KO, Travers S, Barkhoudarian G, Oyesiku NM, Germano IM, Ormond DR. Congress of neurological surgeons systematic review and evidence-based guidelines for the role of surgery for patients with functioning pituitary adenomas. Neurosurgery. 2025;97:24-35.
35. Makarenko S, Alzahrani I, Karsy M, Deopujari C, Couldwell WT. Outcomes and surgical nuances in management of giant pituitary adenomas: a review of 108 cases in the endoscopic era. J Neurosurg. 2022;137:635-46.
36. Khan DZ, Hanrahan JG, Baldeweg SE, Dorward NL, Stoyanov D, Marcus HJ. Current and future advances in surgical therapy for pituitary adenoma. Endocr Rev. 2023;44:947-59.
37. Jho H, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg. 1997;87:44-51.
38. Micko A, Agam MS, Brunswick A, et al. Treatment strategies for giant pituitary adenomas in the era of endoscopic transsphenoidal surgery: a multicenter series. J Neurosurg. 2022;136:776-85.
40. Nieman LK, Biller BMK, Findling JW, et al. Treatment of cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:2807-31.
41. Puig-Domingo M, Bernabéu I, Picó A, et al. Pasireotide in the personalized treatment of acromegaly. Front Endocrinol. 2021;12:648411.
42. Riley G, Scheyer N, Klein M, et al. Prognostic indicators in pituitary adenoma surgery: a comprehensive analysis of surgical outcomes and complications. Front Endocrinol. 2024;14:1327404.
43. Simeoli C, Auriemma RS, Tortora F, et al. The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine. 2015;50:725-40.
44. Starke RM, Williams BJ, Vance ML, Sheehan JP. Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review. Curr Opin Endocrinol Diabetes Obes. 2010;17:356-64.
45. Tabaee A, Anand VK, Barrón Y, et al. Endoscopic pituitary surgery: a systematic review and meta-analysis: Clinical article. J Neurosurg. 2009;111:545-54.
46. Tang OY, Hsueh WD, Eloy JA, Liu JK. Giant pituitary adenoma - special considerations. Otolaryngol Clin North Am. 2022;55:351-79.
47. Wattson DA, Tanguturi SK, Spiegel DY, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014;90:532-9.
48. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9:847-75.
49. Meij BP. Hypophysectomy as a treatment for canine and feline cushing's disease. Vet Clin N Am Anim Pract. 2001;31:1015-41.
50. Sanders K, Kooistra H, Galac S. Treating canine Cushing’s syndrome: current options and future prospects. Vet J. 2018;241:42-51.
51. Brand A, Agolli L, Tas KT, et al. Long-term outcomes of modern radiation therapy for pituitary adenoma - different techniques: single institute experience. J Neurooncol. 2025;175:1039-50.
53. Cucu AI, Costea CF, Perciaccante A, Donell ST, Bianucci R. The evolution of pituitary gland surgery from the ancients to the millennials. World Neurosurg. 2023;180:52-65.
54. Horsley V. Abstracts of the brown lectures, delivered at the University of London. Lecture III: functional nervous disorders due to loss of thyroid gland and pituitary body. Lancet. 1886:3-5.
55. Horsley V. Address in surgery: on the technique of operations on the central nervous system. BMJ. 1906;2:411-23.
57. Cushing H. The pituitary body and its disorders; clinical states produced by disorders of the hypophysis cerebri. An amplification of the Harvey lecture for December, 1910. Available from: https://archive.org/details/pituitarybodyits00cushuoft/page/n9/mode/2up [Last accessed on 12 Jun 2026].
58. Cushing H. Partial hypophysectomy for acromegaly. With remarks on the function of the hypophysis. Ann Surg. 1909;50:1002-17.
59. Cushing H. Studies in intracranial physiology & surgery. The Cameron Prize Lectures. Oxford University Press; 1926, pp. 52-103.
61. Artico M, Pastore FS, Fraioli B, Giuffrè R. The contribution of davide giordano (1864-1954) to pituitary surgery: the transglabellar-nasal approach. Neurosurgery. 1998;42:909-11.
62. Cope VZ. The pituitary fossa, and the methods of surgical approach thereto. Br J Surg. 1916;4:107-44.
64. Macfarlane J, Bashari WA, Senanayake R, et al. Advances in the imaging of pituitary tumors. Endocrinol Metab Clin North Am. 2020;49:357-73.
65. Creemers SG, Hofland LJ, Lamberts SW, Feelders RA. Cushing’s syndrome: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2015;16:1829-44.
66. De Nijs L, Fomekong E, Maiter D, Raftopoulos C. Surgical treatment of cushing’s disease: the lessons learned. In: Di Rocco C, editors. Advances and technical standards in neurosurgery. Cham: Springer Nature Switzerland; 2025. pp. 47-73.
67. Esposito D, Olsson DS, Ragnarsson O, Buchfelder M, Skoglund T, Johannsson G. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary. 2019;22:422-34.
68. Liu JK, Das K, Weiss MH, Laws ER, Couldwell WT. The history and evolution of transsphenoidal surgery. J Neurosurg. 2001;95:1083-96.
69. Lubberink AA. Diagnosis and treatment of canine cushing’s syndrome. Tijdschr Diergeneeskd. 1989;114:37S-9.
70. Meij BP, Voorhout G, Ingh TSVD, Hazewinkel HA, Verlaat JWV. Transsphenoidal hypophysectomy in beagle dogs: evaluation of a microsurgical technique. Vet Surg. 2008;26:295-309.
71. Meij BP, Voorhout G, Van Den Ingh TS, Rijnberk A. Transsphenoidal hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in 7 cats. Vet Surg. 2004;30:72-86.
72. Meij BP, Auriemma E, Grinwis G, Buijtels JJCWM, Kooistra HS. Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy. J Feline Med Surg. 2010;12:406-10.
73. Meij B, Van Der Vlugt-Meijer R, Van Den Ingh T, Rijnberk A. Somatotroph and corticotroph pituitary adenoma (double adenoma) in a cat with diabetes mellitus and hyperadrenocorticism. J Comp Pathol. 2004;130:209-15.
74. Meij BP, Van Der Vlugt-Meijer RH, Van Den Ingh TSGAM, Flik G, Rijnberk A. Melanotroph pituitary adenoma in a cat with diabetes mellitus. Vet Pathol. 2005;42:92-7.
75. Rivenburg R, Owen TJ, Martin LG, Chen AV. Pituitary surgery: changing the paradigm in veterinary medicine in the United States. J Am Anim Hosp Assoc. 2021;57:73-80.
76. Cappabianca P, Cavallo LM, De Divitiis O, Solari D, Esposito F, Colao A. Endoscopic pituitary surgery. Pituitary. 2008;11:385-90.
77. Das A, Sidiqi B, Mennillo L, et al. Automated surgical skill assessment in endoscopic pituitary surgery using real-time instrument tracking on a high-fidelity bench-top phantom. Healthc Technol Lett. 2024;11:336-344.
78. Das A, Khan DZ, Psychogyios D, et al. PitVis-2023 challenge: workflow recognition in videos of endoscopic pituitary surgery. Med Image Anal. 2025:106;103716.
79. Mao Z, Das A, Islam M, et al. PitSurgRT: real-time localization of critical anatomical structures in endoscopic pituitary surgery. Int J Comput Assist Radiol Surg. 2024;19:1053-60.
80. Mamelak AN, Owen TJ, Bruyette D. Transsphenoidal surgery using a high definition video telescope for pituitary adenomas in dogs with pituitary dependent hypercortisolism: methods and results. Vet Surg. 2014;43:369-79.
81. Van Stee LL, Van Rijn SJ, Galac S, Meij BP. Challenges of transsphenoidal pituitary surgery in severe brachycephalic dogs. Front Vet Sci. 2023;10:1154617.
82. Hanson JM, Teske E, Voorhout G, Galac S, Kooistra HS, Meij BP. Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. J Neurosurg. 2007;107:830-40.
83. Lehner L, Czeibert K, Csöndes J, et al. Endoscope-guided transsphenoidal removal of a hypophyseal tumour in a dog. Case study. Magyar Állatorvosok Lapja. 2018;140:535-50. Available from: https://univet.hu/wp-content/uploads/2018/12/MAL-2018-09_content.pdf [Last accessed on 2 Jun 2026].
84. Escauriaza L, Fenn J, Mccue J, et al. A 3-dimensional printed patient-specific surgical guide to facilitate transsphenoidal hypophysectomy in dogs. Front Vet Sci. 2022;9:930856.
85. Roh Y, Kim D, Jeong S, Lee H. Evaluation of the accuracy of three-dimensionally printed patient-specific guides for transsphenoidal hypophysectomy in small-breed dogs. Am J Vet Res. 2022;83:465-72.
86. Santos ERDS, Viana FR, Gonçalves PE, Lima MAC, Lyra CAM, Santos BFDO. Precision in neuronavigation systems: a systematic review and meta-analysis. Arq Bras Neurocir. 2024;43:e325-36.
87. Owen TJ, Chen AV, Frey S, Martin LG, Kalebaugh T. Transsphenoidal surgery: accuracy of an image-guided neuronavigation system to approach the pituitary fossa (sella turcica). Vet Surg. 2018;47:664-71.
88. Van Rijn S, Galac S, Tryfonidou M, et al. The influence of pituitary size on outcome after transsphenoidal hypophysectomy in a large cohort of dogs with pituitary-dependent hypercortisolism. J Vet Intern Med. 2016;30:989-95.
89. Guignat L, Bertherat J. Long-term follow-up and predictors of recurrence of Cushing's disease. J Neuroendocrinol. 2022;34:e13186.
90. Balomenaki M, Vassiliadi DA, Tsagarakis S. Cushing’s disease: risk of recurrence following trans-sphenoidal surgery, timing and methods for evaluation. Pituitary. 2022;25:718-21.
91. Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21:667-78.
92. Law HA, Law AJ, Short TG, et al. Pituitary surgery in New Zealand: a single neurosurgeon case series of 1,224 operations. J Clin Neurosci. 2025;138:111388.
93. Fleseriu M, Biller BMK, Freda PU, et al. A pituitary society update to acromegaly management guidelines. Pituitary. 2020;24:1-13.
94. Fenn J, Kenny PJ, Scudder CJ, et al. Efficacy of hypophysectomy for the treatment of hypersomatotropism-induced diabetes mellitus in 68 cats. J Vet Intern Med. 2021;35:823-33.
95. Van Bokhorst KL, Galac S, Kooistra HS, et al. Evaluation of hypophysectomy for treatment of hypersomatotropism in 25 cats. J Vet Intern Med. 2021;35:834-42.
96. Janelle F, Blanquez-Yeste V, Tran T, et al. Challenges and opportunities for new intraoperative optical techniques in the surgical treatment of pituitary adenomas: a review. J Biomed Opt. 2025;30:080901.
97. Khan DZ, Valetopoulou A, Das A, et al. Artificial intelligence assisted operative anatomy recognition in endoscopic pituitary surgery. NPJ Digit Med. 2024;7:314.
98. Paul R, Johansson R, Kiuru A, et al. Imaging of canine cancers with 18F-2-fluoro-2-deoxy-D-glucose (FDG) suggests further applications for cancer imaging in man. Nucl Med Commun. 1984;5:641-6.
99. Son Y, Kim D, Kang J, et al. High-resolution fluorodeoxyglucose positron emission tomography and magnetic resonance imaging findings of a pituitary microtumor in a dog. Ir Vet J. 2015;68:22.
100. Hansen AE, Mcevoy F, Engelholm SA, Law I, Kristensen AT. FDG PET/CT imaging in canine cancer patients. Vet Radiol Ultrasound. 2010;52:201-6.
101. Yun T, Koo Y, Kim S, et al. Characteristics of 18F-FDG and 18F-FDOPA PET in an 8-year-old neutered male Yorkshire Terrier dog with glioma: long-term chemotherapy using hydroxyurea plus imatinib with prednisolone and immunoreactivity for PDGFR-β and LAT1. Vet Q. 2021;41:163-71.
102. Zhang J, Shi Z, Kang Y, Wu B, Liu X, Zhu H. The application of augmented reality technology in endoscopic pituitary adenoma surgery via nasal approach. Gland Surg. 2025;14:1318-35.
103. Gieger TL, Magestro L, Walz J, Yoshikawa H, Nolan MW. Outcomes of stereotactic radiation therapy versus fractionated radiation therapy in 44 dogs with pituitary masses: a multi-institutional retrospective study (2016-2022). Vet Comp Oncol. 2024;22:429-36.
104. Mondal SB, O’brien CM, Bishop K, Fields RC, Margenthaler JA, Achilefu S. Repurposing molecular imaging and sensing for cancer image-guided surgery. J Nucl Med. 2020;61:1113-22.
105. Litvack ZN, Zada G, Laws ER. Indocyanine green fluorescence endoscopy for visual differentiation of pituitary tumor from surrounding structures: Clinical article. J Neurosurg. 2012;116:935-41.
106. Olesrud I, Halvorsen IJ, Storaker MA, Heck A, Dahlberg D, Wiedmann MKH. Indocyanine green fluorescence in endoscopic transsphenoidal resection of pituitary neuroendocrine tumors: a systematic review. Acta Neurochir. 2025;167:92.
107. Vergeer RA, Theunissen REP, Van Elk T, et al. Fluorescence-guided detection of pituitary neuroendocrine tumor (PitNET) tissue during endoscopic transsphenoidal surgery available agents, their potential, and technical aspects. Rev Endocr Metab Disord. 2022;23:647-57.
108. Staartjes VE, Togni-Pogliorini A, Stumpo V, Serra C, Regli L. Impact of intraoperative magnetic resonance imaging on gross total resection, extent of resection, and residual tumor volume in pituitary surgery: systematic review and meta-analysis. Pituitary. 2021;24:644-56.
109. Wilkie N, Mcsorley G, Creighton C, Sanderson D, Muirhead T, Bressan N. Mixed reality for veterinary medicine: case study of a canine femoral nerve block. In: 2020 42nd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC); 2020 Jul 20-24; Montreal, QC, Canada; pp. 6074-7.
110. Aghapour M, Bockstahler B. State of the art and future prospects of virtual and augmented reality in veterinary medicine: a systematic review. Animals. 2022;12:3517.
111. Li C, Zheng Y, Yuan Y, Li H. Augmented reality navigation-guided pulmonary nodule localization in a canine model. Transl Lung Cancer Res. 2021;10:4152-60.
112. Shimada M, Kurihara K, Tsujii T. Prototype of an augmented reality system to support animal surgery using HoloLens 2. In: 2022 IEEE 4th Global Conference on Life Sciences and Technologies (LifeTech); 2022 Mar 7-9; Osaka, Japan; pp. 335-7.
113. Zhou C, Zhu M, Shi Y, et al. Robot-assisted surgery for mandibular angle split osteotomy using augmented reality: preliminary results on clinical animal experiment. Aesthetic Plast Surg. 2017;41:1228-36.
114. Hunt JA, Heydenburg M, Anderson SL, Thompson RR. Does virtual reality training improve veterinary students’ first canine surgical performance? Vet Rec. 2020;186:562.
115. Ioannou I, Kazmierczak E, Stern L. Comparison of oral surgery task performance in a virtual reality surgical simulator and an animal model using objective measures. In: 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); 2015 Aug 25-29; Milan, Italy; pp. 5114-7.
116. Baskaran V, Štrkalj G, Štrkalj M, Di Ieva A. Current applications and future perspectives of the use of 3D printing in anatomical training and neurosurgery. Front Neuroanat. 2016;10:69.
117. Riutort KT, Clifton W, Damon A, Dove C, Clendenen SR. Construction of an affordable lumbar neuraxial block model using 3D printed materials. Cureus. 2019;11:e6033.
118. Pearce P, Novak J, Wijesekera A, et al. Properties and implementation of 3-dimensionally printed models in spine surgery: a mixed-methods review with meta-analysis. World Neurosur. 2023;169:57-72.
119. Vakharia VN, Vakharia NN, Hill CS. Review of 3-dimensional printing on cranial neurosurgery simulation training. World Neurosur. 2016;88:188-98.
120. Khan DZ, Newall N, Koh CH, et al. Video-based performance analysis in pituitary surgery - part 2: artificial intelligence assisted surgical coaching. World Neurosur. 2024;190:e797-808.
121. Huang J, He R, Khan DZ, et al. Surgical AI copilot: energy-based fourier gradient low-rank adaptation for surgical LLM agent reasoning and planning. arXiv. 2025:arXiv:2503.09474.
122. Iqbal MJ, Javed Z, Sadia H, et al. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer Cell Int. 2021;21:270.
123. Jones OT, Matin RN, Van Der Schaar M, et al. Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review. Lancet Digit Health. 2022;4:e466-76.
124. Liu J, Lei J, Ou Y, et al. Mammography diagnosis of breast cancer screening through machine learning: a systematic review and meta-analysis. Clin Exp Med. 2022;23:2341-56.
125. Kent MS, Rosseel M. Updates on radiation therapy for pituitary tumors. Vet Clin N Am Anim Pract. 2025;55:119-33.
126. Kent MS, Bommarito D, Feldman E, et al. Survival, neurologic response, and prognostic factors in dogs with pituitary masses treated with radiation therapy and untreated dogs. J Vet Intern Med. 2007;21:1027-33.
127. Brearley MJ, Polton GA, Littler RM, Niessen SJM. Coarse fractionated radiation therapy for pituitary tumours in cats: a retrospective study of 12 cases. Vet Comp Oncol. 2006;4:209-17.
128. de Fornel P, Delisle F, Devauchelle P, Rosenberg D. Effects of radiotherapy on pituitary corticotroph macrotumors in dogs: a retrospective study of 12 cases. Can Vet J. 2007;48:481-6.
129. Rapastella S, Morabito S, Sharman M, et al. Effect of pituitary-dependent hypercortisolism on the survival of dogs treated with radiotherapy for pituitary macroadenomas. J Vet Intern Med. 2023;37:1331-40.
130. Hansen KS, Zwingenberger AL, Théon AP, Kent MS. Long-term survival with stereotactic radiotherapy for imaging-diagnosed pituitary tumors in dogs. Vet Radiol Ultrasound. 2018;60:219-32.
131. Marcinowska A, Warland J, Brearley M, Dobson J. Comparison of two coarse fractionated radiation protocols for the management of canine pituitary macrotumor: an observational study of 24 dogs. Vet Radiol Ultrasound. 2015;56:554-62.
132. Kaser-Hotz B, Rohrer CR, Stankeova S, Wergin M, Fidel J, Reusch C. Radiotherapy of pituitary tumours in five cats. J Small Anim Pract. 2002;43:303-7.
133. Körner M, Roos M, Meier VS, et al. Radiation therapy for intracranial tumours in cats with neurological signs. J Feline Med Surg. 2018;21:765-71.
134. Mayer MN, Greco DS, LaRue SM. Outcomes of pituitary tumor irradiation in cats. J Vet Intern Med. 2006;20:1151-4.
135. Sellon R, Fidel J, Houston R, Gavin P. Linear-accelerator-based modified radiosurgical treatment of pituitary tumors in cats: 11 cases (1997-2008). J Vet Intern Med. 2009;23:1038-44.
136. Sawada H, Mori A, Lee P, Sugihara S, Oda H, Sako T. Pituitary size alteration and adverse effects of radiation therapy performed in 9 dogs with pituitary-dependent hypercortisolism. Res Vet Sci. 2018;118:19-26.
137. Goossens MMC, Feldman EC, Theon AP, Koblik PD. Efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc. 1998;212:374-6.
138. Théon AP, Feldman EC. Megavoltage irradiation of pituitary macrotumors in dogs with neurologic signs. J Am Vet Med Assoc. 1998;213:225-31.
139. Wormhoudt TL, Boss M, Lunn K, et al. Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly. J Vet Intern Med. 2018;32:1383-91.
140. Bley CR, Sumova A, Roos M, Kaser-Hotz B. Irradiation of brain tumors in dogs with neurologic disease. J Vet Intern Med. 2005;19:849-54.
141. Gieger TL, Nolan MW. Treatment outcomes and target delineation utilizing CT and MRI in 13 dogs treated with a uniform stereotactic radiation therapy protocol (16 Gy single fraction) for pituitary masses: (2014-2017). Vet Comp Oncol. 2020;19:17-24.
142. Mariani CL, Schubert TA, House RA, et al. Frameless stereotactic radiosurgery for the treatment of primary intracranial tumours in dogs. Vet Comp Oncol. 2013;13:409-23.
143. Park P, Chandler WF, Barkan AL, et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosur. 2004;55:100-7.
144. Green S, Lehrer EJ, Cifarelli CP, et al. Congress of neurological surgeons systematic review and evidence-based guidelines for the role of radiosurgery for patients with functioning pituitary adenomas. Neurosurgery. 2025;97:S36-43.
145. Minniti G, Flickinger J. The risk/benefit ratio of radiotherapy in pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;33:101269.
146. Morsink NC, Klaassen NJM, Meij BP, et al. Case report: radioactive holmium-166 microspheres for the intratumoral treatment of a canine pituitary tumor. Front Vet Sci. 2021;8:748247.
148. Kelsall A, Newell-Price J. Cushing's disease-from Minnie G to key issues in the early 21st century. Lancet Diabetes Endocrinol. 2019;7:959-64.
149. Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by o,p′DDD: survey of 62 cases. N Engl J Med. 1979;300:459-64.
150. Carmichael JD, Fleseriu M. Mifepristone: is there a place in the treatment of Cushing’s disease? Endocrine. 2012;44:20-32.
151. Schofield I, Brodbelt DC, Wilson ARL, et al. Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England. Vet Rec. 2020;186:333-60.
152. Patel J, Eloy JA, Liu JK. Nelson's syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies. Neurosurg Focus. 2015;38:E14.
153. Teshima T, Hara Y, Takekoshi S, et al. Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic–pituitary axis. Domest Anim Endocrinol. 2009;36:32-44.
154. Fracassi F, Corradini S, Floriano D, et al. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane. Vet Rec. 2015;176:49.
155. Galac S, Buijtels JJ, Mol JA, Kooistra HS. Effects of trilostane on the pituitary-adrenocortical and renin–aldosterone axis in dogs with pituitary-dependent hypercortisolism. Vet J. 2010;183:75-80.
156. García San José P, Arenas Bermejo C, Alonso-Miguel D, et al. Survival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane. Vet Rec. 2022;191:e1630.
157. Nagata N, Kojima K, Yuki M. Comparison of survival times for dogs with pituitary-dependent hyperadrenocorticism in a primary-care hospital: treated with trilostane versus untreated. J Vet Intern Med. 2017;31:22-8.
158. De Bruin C, Hanson JM, Meij BP, et al. Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing’s disease. Endocrinology. 2008;149:4357-66.
159. Castillo V, Gómez N, Lalia J, Cabrera Blatter M, García J. Cushing’s disease in dogs: cabergoline treatment. Res Vet Sci. 2008;85:26-34.
160. Scudder CJ, Hazuchova K, Gostelow R, et al. Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus. J Feline Med Surg. 2020;23:131-7.
161. Miceli DD, García JD, Pompili GA, et al. Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism. J Feline Med Surg. 2022;24:1238-44.
162. Golinelli S, Fracassi F, Pöppl AG, et al. Addition of cabergoline to trilostane treatment for dogs with pituitary-dependent hypercortisolism. J Vet Intern Med. 2024;38:1-864. Available from: https://cris.unibo.it/handle/11585/955590 [Last accessed on 12 Jun 2026].
163. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002;143:4123-30.
164. Castillo V, Theodoropoulou M, Stalla J, et al. Effect of SOM230 (Pasireotide) on corticotropic cells: action in dogs with Cushing’S disease. Neuroendocrinology. 2011;94:124-36.
165. Lottati M, Bruyette DS. Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013-2015). J Am Vet Med Assoc. 2018;252:1403-8.
166. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol. 2005;153:135-41.
167. Castillo V, Giacomini D, Páez-Pereda M, et al. Retinoic acid as a novel medical therapy for Cushing’S disease in dogs. Endocrinology. 2006;147:4438-44.
168. Occhi G, Regazzo D, Albiger NM, et al. Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation. Endocrinology. 2014;155:3538-49.
169. Vilar L, Albuquerque JL, Lyra R, et al. The role of isotretinoin therapy for Cushing’s disease: results of a prospective study. Int J Endocrinol. 2016;2016:1-9.
170. Young RB, Bryson MJ, Sweat ML, Street JC. Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem. 1973;4:585-91.
171. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol. 2011;75:585-91.
172. Sbiera S, Leich E, Liebisch G, et al. Mitotane inhibits sterol-o-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156:3895-908.
173. King J, Morton J. Incidence and risk factors for hypoadrenocorticism in dogs treated with trilostane. Vet J. 2017;230:24-9.
174. Fleseriu M, Castinetti F. Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies. Pituitary. 2016;19:643-53.
175. Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab. 2015;100:4146-54.
176. Newell-Price J, Fleseriu M, Pivonello R, et al. Improved clinical outcomes during long-term osilodrostat treatment of cushing disease with normalization of late-night salivary cortisol and urinary free cortisol. J Endocr Soc. 2025;9:bvae201.
177. Feelders RA, Hofland LJ, De Herder WW. Medical treatment of cushing’s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology. 2010;92:111-5.
178. Muthukuda DT, Liyanaarachchi KD, Jayawickreme KP, et al. Etomidate in severe cushing syndrome: a systematic review. J Endocr Soc. 2025;9:bvaf039.
179. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257:1248-51.
180. Sanders K, Mol JA, Kooistra HS, Galac S. Melanocortin 2 receptor antagonists in canine pituitary-dependent hypercortisolism: in vitro studies. Vet Res Commun. 2018;42:283-8.
181. Schimmer BP, White PC. Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Mol Endocrinol. 2010;24:1322-37.
182. Sanders K, Mol J, Slob A, Kooistra H, Galac S. Steroidogenic factor-1 inverse agonists as a treatment option for canine hypercortisolism: in vitro study. Domest Anim Endocrinol. 2018;63:23-30.
183. Brown DR, East HE, Eilerman BS, et al. Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations. Clin Diabetes Endocrinol. 2020;6:18.
185. Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009;160:1003-10.
186. Van Stee L. The growth inhibitory effect of of anti growth hormone (G144K) on canine mammary carcinomasDSpace/Manakin Repository. Available from: https://research-portal.uu.nl/en/publications/the-growth-inhibitory-effect-of-of-anti-growth-hormone-g144k-on-c/ [Last accessed on 12 Jun 2026].
187. Lien Y, Huang H. Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases (1994-2007). J Am Vet Med Assoc. 2008;233:1896-901.
188. Slingerland L, Voorhout G, Rijnberk A, Kooistra H. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus. Domest Anim Endocrinol. 2008;35:352-61.
189. Scudder CJ, Gostelow R, Forcada Y, Schmid HA, Church D, Niessen SJ. Pasireotide for the medical management of feline hypersomatotropism. J Vet Intern Med. 2015;29:1074-80.
190. Gostelow R, Scudder C, Keyte S, et al. Pasireotide long-acting release treatment for diabetic cats with underlying hypersomatotropism. J Vet Intern Med. 2017;31:355-64.
191. Ay SS, Aslan S, Önyay F, et al. Effect of oral misoprostol, alone or in combination with aglepristone, on mid-term pregnancy termination in cats. J Feline Med Surg. 2018;21:714-22.
192. Concannon PW, Yeager A, Frank D, Iyampillai A. Termination of pregnancy and induction of premature luteolysis by the antiprogestagen, mifepristone, in dogs. Reproduction. 1990;88:99-104.
193. Dijkstra KK, Van Den Berg JG, Weeber F, et al. Patient-derived organoid models of human neuroendocrine carcinoma. Front Endocrinol. 2021;12:627819.
194. Van Den Berg MF, Timmermans-Sprang EPM, Viets FC, et al. Canine adrenomedullary and pheochromocytoma organoids: a novel in vitro model. Endocrinology. 2025;166:bqaf114.
195. Ginai M, Elsby R, Hewitt CJ, Surry D, Fenner K, Coopman K. The use of bioreactors as in vitro models in pharmaceutical research. Drug Discov Today. 2013;18:922-35.
